Vycor Medical Reports Revenue Growth Amid Rising Losses and Capital Deficiencies in Q1 2025

Vycor Medical, Inc. (OTCBB: VYCO) recently released its quarterly financial results for the period ended March 31, 2025, showing a mixture of positive growth and significant challenges.

Key Statistics:

• Revenue: $436,378 (up 30% from $336,968 in Q1 2024)
• Gross Profit: $358,534 (up 20% from $299,962 in Q1 2024)
• Operating Loss: $12,806 (up from a loss of $9,532 in Q1 2024)
• Net Loss: $38,563 (compared to $30,608 in Q1 2024)
• Cash at End of Period: $61,049 (down from $105,648 at year-end 2024)
• Working Capital Deficiency: $4,052,879 as of March 31, 2025
• Common Shares Outstanding: 33,372,796

Positive Aspects of Income Statement:

• Revenue growth primarily driven by increased sales in the Vycor Medical segment (31% increase) and some growth in international markets.
• Gross profit margin remains strong, despite a slight decline attributed to costs of new production validation and a less favorable sales mix.
• Increase in cash flow from operations results from better management of accounts receivable.

Negative Aspects of Income Statement:

• Operating loss has increased, indicating rising costs not fully offset by revenue growth, particularly due to increased selling, general, and administrative expenses.
• Significant net loss increases concern over the company's ability to manage its ongoing expenses, especially with a working capital deficiency that raises doubts about its capability to continue as a going concern.
• Dependency on related party financing introduces risks associated with personal financial conditions of major shareholders.

Overall, while Vycor Medical (OTCBB: VYCO) is experiencing revenue growth, the increase in losses and working capital deficiencies are critical issues that investors should monitor closely as the company navigates its financial landscape.